STAAR Surgical Company (NASDAQ:STAA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On February 21, 2019, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter and fiscal year ended December 28, 2018, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
This information and the information contained in the press release shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report, and Exhibit 99.1 are not incorporated by reference into any filings of STAAR made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.
Item 9.01 Financial Statements and Exhibits
STAAR SURGICAL CO Exhibit
EX-99.1 2 tv514182_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STAAR Surgical Reports Fourth Quarter and Full Year 2018 Results Fourth Quarter ICL Sales Rise 41%; Full Year 2018 ICL Sales Rise 48% GAAP Net Income of $0.02 Per Share in Fourth Quarter; $0.11 Per Share for Full Year 2018 MONROVIA,…
To view the full exhibit click here
About STAAR Surgical Company (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). It sells its products in approximately 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
